Walmart U.S. Sales Growth Hits 5-Year Low on Drug Price Decline

Key Facts

Amid shifting dynamics in the American retail sector, Walmart Inc. reported a notable deceleration in its domestic sales performance. The company’s U.S. comparable sales grew by 2.6% in the second quarter, marking the lowest growth rate in over five years. This slowdown was primarily driven by falling pharmaceutical prices, which weighed on overall performance and caused the retailer to miss market expectations despite growth in its eCommerce segment.

The decline in drug prices highlights a specific headwind for the supermarket chain's pharmacy business, according to financial reports. This internal slowdown coincides with broader economic data showing U.S. Retail Sales contracted by 0.6% in August, per market data. Such figures suggest a challenging environment for major retailers as they navigate fluctuating consumer demand and pricing pressures across core product categories.

Walmart (WMT) shares stood at $114.30 at the close of August 19, 2026, after trading within a daily range of $113.99 to $116.87. Traders should monitor upcoming consumer sentiment trends, as recent data from the Michigan Consumer Sentiment index showed a reading of 51, falling short of the 54.5 forecast and indicating potential caution in future retail spending.